Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07215624 · ClinicalTrials.gov registry record

Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study

A clinical trial of Malignant Female Reproductive System Neoplasm and Malignant Digestive System Neoplasm, sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
500
Enrollment target
20
Study locations

NCT07215624 is a study of Malignant Female Reproductive System Neoplasm and Malignant Digestive System Neoplasm that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 500 participants, above the 377-participant average among 18 other Malignant Female Reproductive System Neoplasm trials with a reported enrollment target (33% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07215624, a study of Malignant Female Reproductive System Neoplasm and Malignant Digestive System Neoplasm, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
500 participants
Enrollment target
20
Study locations

Study Summary

This study evaluates the use of extended venous thromboembolism prophylaxis (ePPx) following abdominopelvic cancer surgery within the NCI Community Oncology Research Program (NCORP) network, targeting surgeons and surgical advanced practice providers (APPs).

Conditions Studied

Malignant Female Reproductive System Neoplasm Malignant Digestive System Neoplasm Malignant Genitourinary System Neoplasm

Interventions

  • OTHER Non-Interventional Study

Study Locations (20)

Iowa

  • Mercy Hospital - Cedar Rapids
  • Oncology Associates at Mercy Medical Center - Cedar Rapids
  • Blank Children's Hospital - Des Moines
  • Mercy Medical Center - Des Moines - Des Moines
  • Iowa Lutheran Hospital - Des Moines

Delaware

  • Helen F Graham Cancer Center - Newark
  • Medical Oncology Hematology Consultants PA - Newark
  • Christiana Care Health System-Christiana Hospital - Newark

Georgia

  • Northside Hospital - Atlanta
  • Augusta University Medical Center - Augusta
  • Northside Hospital - Gwinnett - Lawrenceville

Michigan

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor - Ann Arbor
  • Chelsea Hospital - Chelsea
  • Trinity Health Saint Mary Mercy Livonia Hospital - Livonia

Minnesota

  • Sanford Joe Lueken Cancer Center - Bemidji
  • Essentia Health Saint Joseph's Medical Center - Brainerd

Arkansas

  • Mercy Hospital Fort Smith - Fort Smith

Illinois

  • Carle Cancer Center - Urbana

Maine

  • MaineHealth Maine Medical Center- Scarborough - Scarborough

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2026-01-15
Est. Completion 2027-06-01

Sponsor

Wake Forest University Health Sciences

1,140 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07215624

The ClinicalTrials.gov registry entry for NCT07215624 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 377-participant average among 18 other Malignant Female Reproductive System Neoplasm trials with a reported enrollment target (33% higher). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Malignant Female Reproductive System Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.

NCT07215624 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Iowa, Delaware, Georgia.

Frequently Asked Questions

What is clinical trial NCT07215624 about?

NCT07215624 is a clinical study titled "Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study". This study evaluates the use of extended venous thromboembolism prophylaxis (ePPx) following abdominopelvic cancer surgery within the NCI Community Oncology Research Program (NCORP) network, targeting surgeons and surgical advanced practice providers (APPs).

What is the current status of trial NCT07215624?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2026-01-15. Estimated completion is 2027-06-01.

What conditions does trial NCT07215624 study?

This clinical trial studies the following conditions: Malignant Female Reproductive System Neoplasm, Malignant Digestive System Neoplasm, Malignant Genitourinary System Neoplasm.

What interventions are being tested in trial NCT07215624?

The interventions under investigation include: Non-Interventional Study (OTHER).

Who is sponsoring clinical trial NCT07215624?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07215624 being conducted?

This trial has 20 study locations across Arkansas, Delaware, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Malignant Female Reproductive System Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Malignant Female Reproductive System Neoplasm

All registered trials for this condition

Malignant Digestive System Neoplasm

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.